Back to News
Market Impact: 0.3
Precision BioSciences, Inc. Announces PBGENE-HBV Phase 2 Advancement and PBGENE-DMD Safety Update
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Precision BioSciences reported successful preliminary data from its ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV for chronic hepatitis B. As of the September 28, 2026 data cutoff, 25 patients had received 59 total administrations; the article provides no further efficacy or safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
DTIL0.65
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook